WAUCONDA, IL ADDRESS 

Family Medicine Specialists
431 West Liberty Street
Wauconda, IL 60081
847-772-4622

 CIS Research in  Gurnee, IL are conducting a Heart Failure Study

For more information, fill out the questionnaire below or call us at  847-599-2492

About This Study

What is Obesity?

Obesity is a medical condition characterized by an excessive amount of body fat, increasing the risk of various health issues such as heart disease, diabetes, and hypertension. It affects individuals of all ages but is most prevalent among adults, with higher rates observed in certain racial and ethnic groups. This is an Internal Medicine trial. To learn more about obesity, click here.

About This Study

What is Obesity?

Obesity is a medical condition characterized by an excessive amount of body fat, increasing the risk of various health issues such as heart disease, diabetes, and hypertension. It affects individuals of all ages but is most prevalent among adults, with higher rates observed in certain racial and ethnic groups. This is an Internal Medicine trial. To learn more about obesity, click here.

Have you been diagnosed with Psoriatic Arthritis?

Trial Information:

The INSPIRE 1 trial by SunPharma will test how effective, safe and tolerable the study drug, tildrakizumab, is compared to placebo in the treatment of psoriatic arthritis. Tildrakizumab is an antibody being tested or used for different conditions such as psoriatic arthritis.These are conditions related to how your immune system is functioning. An antibody is a protein made by the body’s immune (defense) system to fight infection by binding other proteins and molecules.

Have you been diagnosed with Rheumatoid Arthritis?

Trial Information:

The Xbiotech 2021-PT055 study will assess the safety and effectiveness of Natrunix (human antibody preparation) in combination with Methotrexate (MTX) to determine the ACR 20 response rate. ACR response is the measure of improvement in percentage of RA disease. The disease activity is checked at two different time points, one before the study drug and one after the study drug.

Have you been diagnosed with Acute Coronary Syndrome (ACS)?

Trial Information:

The LIBREXIA 3003 study by Janssen will study if an experimental drug called milvexian is safe and useful in reducing risk of developing blood clots, stroke, or another heart attach among subjects with a recent heart attack or angina episode, compared to placebo (tablet with no active drug) in addition to standard medication.

Have you been diagnosed with Atrial Fibrillation (AFib)?

Trial Information:

The LIBREXIA 3002 study by Janssen will compare the effects of an experimental drug, milvexia, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the brain (non-central nervous system (CNS) systemic embolism) in participants with atrial fibrillation.